June 2014

Dear shareholders and prospective shareholders,

Earlier this month, CRH Medical chairman Tony Holler, CEO Edward Wright and I marketed the company in Toronto for two days.

We spent the first day sharing the story with a number of buy and sell side accounts on Bay Street. Thanks to our friends at PI Financial (a Vancouver-based broker dealer), as part of our marketing, we managed to land an introductory meeting with a prominent fund with a few billion dollars of assets under management.

The fund’s analyst was very interested in our market opportunity for the O’Regan System and wants to see us grow our market share in the coming quarters. If they decide to become shareholders, they will be aligned with our plans to grow the company.

The following day, we attended the third annual Bloom Burton & Co. Healthcare Investor Conference. The conference featured Canada’s premier publicly-traded companies and attracted Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.

Edward delivered a 30-minute, formal company presentation to a full room at 11 am. Before and after the presentation, Tony, Edward and I participated in one-on-one meetings with several high quality, healthcare-focused funds.

Much of the feedback centered on CRH’s plans to continue growing top-line revenue organically with the O’Regan System, and potentially through M&A with additional products and or services.

Gastroenterology Conferences

Earlier this month, CRH attended the American College Of Gastroenterology Eastern Regional Meeting in Washington, D.C. This GI- focused conference is typically busier than many of the other smaller conferences we attend and this year was no exception.

Our team generated a number of new customer leads and we met with several of our current customers. Though July will be quiet in this department, we look forward to August when the meetings begin to ramp up again.

 

We look forward to sharing the July edition of the CRH Investor Bulletin with you, and as always, we appreciate your interest and support.

Adam Peeler
Media and Investor Relations
TMX Equicom
416.815.0700 x 225
apeeler@tmxequicom.com

We're a stable, profitable company respected by both patients and physicians. Learn more »